Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: germinaro m. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease.
Sands BE, Panés J, Feagan BG, Zhang H, Vetter ML, Mathias SD, Huang KG, Johanns J, Germinaro M, Sahoo A, Terry NA, Han C. Sands BE, et al. Among authors: germinaro m. Value Health. 2024 Sep;27(9):1225-1234. doi: 10.1016/j.jval.2024.05.019. Epub 2024 Jun 4. Value Health. 2024. PMID: 38843977 Free article.
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
Feagan BG, Sandborn WJ, Sands BE, Liu Y, Vetter M, Mathias SD, Huang KG, Johanns J, Germinaro M, Han C. Feagan BG, et al. Among authors: germinaro m. J Patient Rep Outcomes. 2023 Nov 14;7(1):115. doi: 10.1186/s41687-023-00645-0. J Patient Rep Outcomes. 2023. PMID: 37962770 Free PMC article.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Among authors: germinaro m. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group. Feagan BG, et al. Among authors: germinaro m. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1. Lancet Gastroenterol Hepatol. 2023. PMID: 36738762 Clinical Trial.
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
Uzzan M, Bouhnik Y, Abreu M, Ahmad HA, Adsul S, Carlier H, Dubinsky M, Germinaro M, Jairath V, Modesto I, Mortensen E, Narula N, Neimark E, Oortwijn A, Protic M, Rubin DT, Oh YS, Wichary J, Peyrin-Biroulet L, Reinisch W. Uzzan M, et al. Among authors: germinaro m. J Crohns Colitis. 2023 Jul 5;17(7):1066-1078. doi: 10.1093/ecco-jcc/jjad020. J Crohns Colitis. 2023. PMID: 36738443
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Sandborn WJ, et al. Among authors: germinaro m. Gastroenterology. 2022 May;162(6):1650-1664.e8. doi: 10.1053/j.gastro.2022.01.047. Epub 2022 Feb 5. Gastroenterology. 2022. PMID: 35134323 Free article. Clinical Trial.
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Weinstein SF, et al. Among authors: germinaro m. J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596.e3. doi: 10.1016/j.jaip.2018.08.021. Epub 2018 Sep 5. J Allergy Clin Immunol Pract. 2019. PMID: 30193936 Clinical Trial.
15 results